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CYSTIC FIBROSIS
Fatime Sylla
Otterbein University, Westerville, Ohio
Overview
Cystic fibrosis (CF) is one of the lethal
autosomal recessive disease that “
causes persistent lung infections and
limits the ability to breathe overtime”
(Cystic Fibrosis foundation, 2018).
Facts about Cystic Fibrosis
✓ Life Expectancy of people with
CF is mid- to late 30s
✓ More than 30, 000 of people
live with CF ( 70,000
worldwide)
✓ Approximately, 1,000 new
cases are diagnosed each year
✓ More than 75 % of people with
CF are diagnosed by age 2
✓ More than half of CF population
is 18 and older (Cystic Fibrosis
Foundation, 2018).
✓ Lungs disease are 80% of CF
mortality (Cutting, 2015, p.45)

Understand Cystic Fibrosis
signs, symptoms and complications

Pathophysiology
CF affects the cells that produce
mucus, sweat and digestive juices.
These secreted fluids are normally thin
and slippery. But in people with CF, a
defective gene causes the secretions to
become sticky and thick. Instead of
acting as a lubricant, the secretions plug
up tubes, ducts and passageways
especially in the lungs and pancreas
(Mayo Clinic, 2016).
CF is caused by defects in the cystic
fibrosis gene, which codes for a protein
transmembrane conductance regulator
(CFTR) that functions as a chloride
channel and is regulated by cyclic
adenosine monophosphate (cAMP).
Mutations in the CFTR gene result in
abnormalities of cAMP-regulated
chloride transport across epithelial cells

on mucosal surfaces (Sharma, 2018).
Almost 2000 disease causing
mutations have been identified in
people with cystic fibrosis to date, but
most of the cases can be classified into
six classes according to the genetic
mutations as shown in table 1 (Brodie,
Haq, Roberts and Elborn, 2015, p.2).
The variability of mutations are
linked to the severity of the disease.
However, two individuals with the
same CFTR genotype may follow a
different natural history and trajectory
of their lung disease due to
environmental, microbiological and
socioeconomic factors, as well as
adherence with treatment and
modifier genes (Brodie et al., 2015).

“The signs and symptoms of cystic
fibrosis (CF) vary from person to person
(..)” (NHLBI, 2018).
✓
✓
✓
✓
✓
✓

Respiratory symptoms
Persistent cough that produces
thick mucus
Wheezing
Breathlessness
Exercise intolerance
Repeated lung infections
Inflamed nasal passage or stuffy
nose (Mayo clinic, 2016)

Symptoms vary over time and as
disease gets worse, they are more severe
(NHLBI, 2018).
Digestive symptoms
Foul-smelling greasy stools
Poor weight gain and growth
Intestinal blockage, particularly in
newborns
✓ Severe constipation
✓ Rectal prolapse (Mayo Clinic, 2016)
✓
✓
✓

Management
There is no cure. The goal of
treatment include preventing and
controlling lungs infection, loosening and
removing thick an sticky mucus from
lungs, preventing or treating blockage in
the intestines, providing enough
nutrition an preventing dehydration.
This requires a multidisciplinary
approach that involves a medical team of
nurses, physical therapy , dietitians and
social workers. Also, depending on the
severity of symptoms, the CF treatment
may requires long stay at he hospital
(NHLBI, 2018, Treatment).
✓

✓
✓

Risk factors
✓ Race: commonly in white of
Northern Europe ( but occurs
in all races and ethnicities)
✓ Males and females
✓ More than 10 million
Americans are carriers of a
faulty CF gene (NIH, 2018).
✓ Family history: Inherited
disorder, both parents must
have a least one copy of the
defective gene for the child to
have the disease or (Cystic
Fibrosis Foundation, 2018)

✓

✓
✓

Table 1
Summary of different classes of CFTR mutations
Mutation Class
I

Nature of defect
CFTR protein synthesis

II

CFTR protein processing

III

CFTR channel gating

IV

CFTR channel conductance

V

Reduced CFTR protein
production
CFTR protein turnover at cell
surface

VI

Diagnosis
Functional consequence
Reduced CFTR protein
expression
Misfolded CFTR not
transported at to cell surface
Reduced/lack of CFTR
channel opening
Misshaped CFTR pore
restricts Cl− movement
Very low levels of CFTR
protein
Functional but unstable CFTR
protein at cell surface

Note. Adapted from “Targeted Therapies to Improve CFRT Function in Cystic fibrosis” by M. Brodlie,
I. J. Hag, K. Roberts and J. S. Elborn, 2015, Genome Medicine, p. 2.

In addition to clinical symptoms, doctors diagnose CF based on multiple tests
including:
✓ Newborn screening (blood sample is checked for higher than normal levels of a
chemical (immunoreactive trypsinogen, or IRT) released by the pancreas)
✓ Sweat test
✓ Other tests:
▪
Genetic tests ( for type of CFTR defect)
▪
Chest x-ray
▪
Sinus x-ray
▪
Lung functions test
▪
Sputum culture
✓ Prenatal screening
✓ CF carrier testing ( detect faulty genes 9 out of 10 cases) ( NHLBI, 2018,
diagnosis).

✓

✓

Type of treatments
Chest physical therapy that is called
clapping or percussion involving
pounding chest and back over and
over with hands or devices
Aerobic Exercise
Treatment for advanced lung
disease ( oxygen therapy or
transplant)
Pulmonary rehabilitation that
include exercise training, ,
nutritional counseling, education on
lung disease or condition and how
to manage it, energy-conserving
techniques, breathing strategies,
psychological counseling and/or
group support
Nutritional therapy with a wellbalanced diet that's rich in calories,
fat, and protein ( NHLBI, 2018)
Traditional medicines:
•
Antimicrobial agents
•
Anti-inflammatory
agents
•
Bronchodilators
•
Oral pancreatic
enzymes (Mayo clinic,
2016, Medications).
Precision medicines such as gene
therapies for improving
Transmembrane Regulator (CFRT)
Function (e.g. Ivacaftor) (Murphy &
Caraher, 2016, p.2) or gene therapy
for restoration of normal CFTR
function (Murphy & Caraher, 2016,
p.9)
Treatment of common
complications such as diabetes and
Osteoporosis (NHLBI, 2018).

Conclusion
Cystic fibrosis is a complex disease
that requires the dedication of healthcare
providers that focus on providing
specialized care and disease
management. CF patients live depend on
combination therapies that help loosen
and get rid of the thick mucus that can
build up in the lungs, open the airways
or thin the mucus through inhaled
medicines, and improve the absorption
of vital nutrients by providing pancreatic
enzymes supplement capsules (Cystic
Fibrosis Foundation, 2018, treatment).
However, as Garner, Gray, self and
Wagener (2017) outlined, it is vital for
patients to fully commit to their
treatment to ensure positive outcomes
by creating specialized individual plans.
Care team must utilize strategies that
increase communication with patients to
“establish and document realistic,
meaningful, and achievable goals; and
ensure follow-up on progress and
barriers to progress” (p.766).
Finally, despite tremendous
achievements in the fight for the cure of
CF, too many lives are still being lost.
And the more one understands the
underlying mechanism of CF, the better
equipped one is to handle this illness. In
this perspective, genetic research with
precision medicine offers the key to not
only finding treatments that improve
quality of life of CF patients but also in
the fight of finding the cure for this
terrible disease.
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